Dizal's Zegfrovy clinches landmark phase 3 win in NSCLC subtype, setting up challenge to J&J's Rybrevant
23rd March 2026 Uncategorised 0Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure on the pharma giant’s injectable Rybrevant in non-small cell lung cancer.
More: Dizal's Zegfrovy clinches landmark phase 3 win in NSCLC subtype, setting up challenge to J&J's Rybrevant
Source: fierce